Resultats globals: 3 registres trobats en 0.04 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
10 p, 2.9 MB Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer / Duro-Sánchez, Santiago (Institut Hospital del Mar d'Investigacions Mèdiques) ; Nadal-Serrano, Mercedes (Centro de Investigación Biomédica en Red de Cáncer) ; Lalinde-Gutiérrez, Marta. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Arenas, Enrique J (Centro de Investigación Biomédica en Red de Cáncer) ; Bernadó Morales, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ; Morancho, Beatriz (Centro de Investigación Biomédica en Red de Cáncer) ; Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ; Pérez-Ramos, Sandra (Vall d'Hebron Institut d'Oncologia) ; Escrivá-de-Romaní, Santiago (Vall d'Hebron Institut d'Oncologia) ; Gandullo-Sánchez, Lucía (Vall d'Hebron Institut d'Oncologia) ; Pandiella, Atanasio (Instituto de Biología Molecular y Celular del Cáncer (Barcelona)) ; Esteve-Codina, Anna (Universitat Pompeu Fabra) ; Rodilla, Verónica (Vall d'Hebron Institut d'Oncologia) ; Dijcks, Fred .A. (Byondis B.V. (Holanda)) ; Dokter, Wim .H.A. (Byondis B.V. (Holanda)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Saura, Cristina (Institut Hospital del Mar d'Investigacions Mèdiques) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
Antibody-drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. [...]
2022 - 10.1158/0008-5472.CAN-22-0787
Cancer research, Vol. 82 Núm. 24 (12 2022) , p. 4670-4679  
2.
15 p, 1.5 MB Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O· production in cancer cells / Cordani, Marco (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; Butera, Giovanna (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Dando, Ilaria (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Torrens-Mas, Margalida (Institut d'Investigació Sanitària de Palma) ; Butturini, Elena (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Pacchiana, Raffaella (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Oppici, Elisa (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Cavallini, Chiara (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ; Gasperini, Sara (Section of General Pathology, University of Verona. Department of Medicine) ; Tamassia, Nicola (Section of General Pathology, University of Verona. Department of Medicine) ; Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ; Coan, Michela (National Cancer Institute (Aviano, Itàlia)) ; Rossi, Davide (Institute of Oncology Research) ; Gaidano, Gianluca (University of Eastern Piedmont. Division of Hematology, Department of Translational Medicine) ; Caraglia, Michele (Department of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy) ; Mariotto, Sofia (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Spizzo, Riccardo (National Cancer Institute (Aviano, Itàlia)) ; Roca, Pilar (Institut d'Investigació Sanitària de Palma) ; Oliver, Jordi (Institut d'Investigació Sanitària de Palma) ; Scupoli, Maria Teresa (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ; Donadelli, Massimo (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Universitat Autònoma de Barcelona
The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function isoforms actively promote cancer malignancy. A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status. [...]
2018 - 10.1038/s41416-018-0288-2
British Journal of Cancer, Vol. 119 (october 2018) , p. 994-1008  
3.
14 p, 3.0 MB The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1 / Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ; Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ; Luque, Antonio (Vall d'Hebron Institut d'Oncologia) ; Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ; Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Dijcks, Fred A. (Preclinical R&D, The Netherlands) ; Dokter, Wim H. A. (Preclinical R&D, The Netherlands) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Saura, Cristina (Hospital Universitari Vall d'Hebron) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. [...]
2020 - 10.3390/cancers12030670
Cancers, Vol. 12 (march 2020)  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.